define('DISALLOW_FILE_EDIT', true);
define('DISALLOW_FILE_MODS', true);<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>industries &#8211; animal-health-online.com</title>
	<atom:link href="https://www.animal-health-online.de/int/category/industries/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.animal-health-online.de/int</link>
	<description>news on animal-health and more</description>
	<lastBuildDate>Tue, 28 Aug 2012 18:10:19 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=4.9.25</generator>
	<item>
		<title>Lilly to Acquire European Rights to Pfizer Animal Health Assets +++ Deal Provides Strategic Fit For Elanco, Lilly&#8217;s Animal Health Division</title>
		<link>https://www.animal-health-online.de/int/2010/03/08/lilly-to-acquire-european-rights-to-pfizer-animal-health-assets-deal-provides-strategic-fit-for-elanco-lillys-animal-health-division/113/</link>
		<pubDate>Mon, 08 Mar 2010 20:44:18 +0000</pubDate>
		<dc:creator><![CDATA[admin]]></dc:creator>
				<category><![CDATA[industries]]></category>
		<category><![CDATA[products]]></category>

		<guid isPermaLink="false">http://www.animal-health-online.de/int/?p=113</guid>
		<description><![CDATA[<img src="http://1.2.3.9/bmi/newsroom.lilly.com/common/alerts/LLY/default/logo.gif" alt="Lilly"  style="float:left; margin-right:5px; margin-bottom:5px; border="0" />GREENFIELD, Ind., March 8, 2010 /PRNewswire via COMTEX News Network/ -- Elanco, the animal health division of Eli Lilly and Company (NYSE: LLY), today announced that Lilly has signed an agreement to acquire the European rights to a portfolio of certain Pfizer Animal Health products. The products, including vaccines, parasiticides and feed additives, are used in both the production animal and companion animal markets.]]></description>
		</item>
		<item>
		<title>symposium shows importance of MANAGING Bovine Respiratory Disease ‘right the first time’ WITH COMBINATION TREATMENT</title>
		<link>https://www.animal-health-online.de/int/2010/01/13/symposium-shows-importance-of-managing-bovine-respiratory-disease-right-the-first-time-with-combination-treatment/104/</link>
		<pubDate>Wed, 13 Jan 2010 19:37:04 +0000</pubDate>
		<dc:creator><![CDATA[admin]]></dc:creator>
				<category><![CDATA[animal-health]]></category>
		<category><![CDATA[cattle]]></category>
		<category><![CDATA[industries]]></category>
		<category><![CDATA[products]]></category>

		<guid isPermaLink="false">http://www.animal-health-online.de/int/?p=104</guid>
		<description><![CDATA[BOXMEER (Netherlands), January 13, 2010 – Treatment of Bovine Respiratory Disease (BRD) in cattle with a combination preparation consisting of the anti-infective drug florfenicol and the anti-inflammatory drug flunixin meglumine (RESFLOR® Solution for Injection), results in control of bacterial growth, reduction of fever and reduction of lung consolidation. This conclusion was drawn last month at [&#8230;]]]></description>
		</item>
	</channel>
</rss>